 |
|
|
| |
Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV Aged ≥ 50 Years: 48-Week Follow-Up From Four Phase 3 Studies
|
| |
| |
15th International Workshop on Aging & HIV; October 24–25, 2024; Washington, DC, USA
Cissy M Kityo1, Samir K Gupta2, Princy N Kumar3, Amy R Weinberg4, Bhumi Gandhi-Patel4, Hui Liu4, Jason T Hindman4, Jürgen K Rockstroh5
1Joint Clinical Research Centre, Kampala, Uganda; 2Indiana University School of Medicine, Indianapolis, IN, USA; 3Georgetown University Medical Center, Washington, DC, USA;
4Gilead Sciences, Inc., Foster City, CA, USA; 5University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany
|
| |
|
|
|
|
|
